A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine

References

• Andersson BS, Aw TY, Jones DP. (1987). Mitochondrial transmembrane potential and pH gradient during anoxia. Am J Physiol 252:C349–55
   PubMed Web of Science ®Google Scholar
• Basañez G, Soane L, Hardwick JM. (2012). A new view of the lethal apoptotic pore. PLoS Biol 10:e1001399
   PubMed Web of Science ®Google Scholar
• Bonura F, Di Lisi D, Novo S, et al. (2012). Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist. Cardiovasc Toxicol 12:93–107
   PubMed Web of Science ®Google Scholar
• Calik A, Celiker E, Velibey Y, et al. (2012). Initial dose effect of 5-flurouracil: rapidly improving severe, acute toxic myopericarditis. Am J Emerg Med 30:257.e1–.e3
   Web of Science ®Google Scholar
• Cunha-Junior GF, De Marco L, Bastos-Rodrigues L, et al. (2013). (13)C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients. Cancer Chemother Pharmacol 72:1273–82
   PubMed Web of Science ®Google Scholar
• De Forni M, Malet-Martino M, Jaillais P, et al. (1992). Cardiotoxicity of high-dose continuous infusion florouracil: a prospective clinical study. J Clin Oncol 10:1795–801
   PubMed Web of Science ®Google Scholar
• Dechant C, Baur M, Böck R, et al. (2012). Acute reversible heart failure caused by coronary vasoconstriction due to continuous 5-fluorouracil combination chemotherapy. Case Rep Oncol 5:296–301
   Google Scholar
• Eskilsson J, Albertsson M, Mercke C. (1988). Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. Radiother Oncol 13:41–6
   PubMed Web of Science ®Google Scholar
• Fernández-Martos C, Nogué M, Cejas P, et al. (2012). The role of capecitabine in locally advanced rectal cancer treatment: an update. Drugs 72:1057–73
   PubMed Web of Science ®Google Scholar
• Formica V, Leary A, Cunningham D, Chua YJ. (2006). 5-Fluorouracil can cross brain-blood barrier and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma. Cancer Chemother Pharmacol 58:276–78
   PubMedGoogle Scholar
• Galati G, Teng S, Moridani MY, et al. (2000). Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug Metabol Drug Interact 17:311–49
   PubMedGoogle Scholar
• Gogvadze V, Orrenius S, Zhivotovsky B. (2006). Multiple pathways of cytochrome c release from mitochondria in apoptosis. Biochim Biophys Acta 1757:639–47
   PubMed Web of Science ®Google Scholar
• Hissin J, Hilf R. (1976). A fluorometric method for determination of oxidised and reduced glutathione in tissues. Anal Biochem 74:214–26
   PubMed Web of Science ®Google Scholar
• Jensen SA, Sørensen JB. (2006). Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 58:487–93
   PubMed Web of Science ®Google Scholar
• Kelso EJ, McDermott BJ, Silke B. (1995). Actions of the novel vasodilator, flosequinan, in isolated ventricular cardiomyocytes. J Cardiovasc Pharmacol 25:376–86
   PubMed Web of Science ®Google Scholar
• Koukourakis GV, Kouloulias V, Koukourakis MJ, et al. (2008). Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review. Molecules 13:1897–922
   PubMed Web of Science ®Google Scholar
• Kwak HB. (2013). Effects of aging and exercise training on apoptosis in the heart. J Exerc Rehabil 9:212–19
   PubMedGoogle Scholar
• Lamberti M, Porto S, Marra M, et al. (2012). 5-Fluorouracil induces apoptosis in rat cardiomyocytes through intracellular oxidative stress. J Exp Clin Cancer Res 31:60. doi: 10.1186/1756-9966-31-60
   PubMed Web of Science ®Google Scholar
• Leist M, Single B, Castoldi AF, et al. (1997). Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 185:1481–6
   PubMed Web of Science ®Google Scholar
• Lieutaud T, Brain E, Golgran-Toledano D, et al. (1996). 5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? Eur J Cancer 32a:368–9
   Google Scholar
• Meydan N, Kundak I, Yavuzsen T, et al. (2005). Cardiotoxicity of de Gramont’s regimen: incidence, clinical characteristics and long-term follow-up. Jpn J Clin Oncol 35:265–70
   PubMed Web of Science ®Google Scholar
• O’Brien PJ, Siraki AG. (2005). Accelerated cytotoxicity mechanism screening using drug metabolising enzyme modulators. Curr Drug Metab 6:101–9
   PubMed Web of Science ®Google Scholar
• Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. (2013). Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 39:974–84
   PubMed Web of Science ®Google Scholar
• Pourahmad J, Ross S, O’Brien PJ. (2001). Lysosomal involvement in hepatocyte cytotoxicity induced by Cu2+ but not Cd2+. Free Radic Biol Med 30:89–97
   PubMed Web of Science ®Google Scholar
• Pourahmad J, Hosseini MJ, Eskandari MR, et al. (2010). Mitochondrial/lysosomal toxic cross-talk plays a key role in cisplatin nephrotoxicity. Xenobiotica 40:763–71
   PubMed Web of Science ®Google Scholar
• Raschi E, Vasina V, Ursino MG, et al. (2010). Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther 125:196–218
   PubMed Web of Science ®Google Scholar
• Reigner B, Blesch K, Weidekamm E. (2001). Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85–104
   PubMed Web of Science ®Google Scholar
• Rezkalla S, Kloner R, Ensley J, et al. (1989). Continuous ambulatory ECG monitoring during flurouracil therapy: a prospective study. J Clin Oncol 7:509–14
   PubMed Web of Science ®Google Scholar
• Robben N, Pippas A, Moore J. (1993). The syndrome of 5-fluorouracil cardiotoxicity. Cancer 71:493–509
   PubMed Web of Science ®Google Scholar
• Saif MW, Shah MM, Shah AR. (2009). Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 8:191–202
   PubMed Web of Science ®Google Scholar
• Sakahira H. (1998). Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 391:96–9
   PubMed Web of Science ®Google Scholar
• Smith MT, Thor H, Hartzell P, Orrenius S. (1982). The measurement of lipid peroxidation in isolated hepatocytes. Biochem Pharmacol 31:19–26
   PubMed Web of Science ®Google Scholar
• Sorrentino MF, Kim J, Foderaro AE, Truesdell AG. (2012). 5-fluorouracil induced cardiotoxicity: review of the literature. Cardiol J 19:453–58
   PubMed Web of Science ®Google Scholar
• Stewart T, Pavlakis N, Ward M. (2010). Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J 40:303–7
   PubMed Web of Science ®Google Scholar
• Stupans I, Richards DA, McClure MT. (1995). Effects of 5-fluorouracil treatment on rat liver microsomal enzymes. Xenobiotica 25:1–8
   PubMed Web of Science ®Google Scholar
• Talapatra K, Rajesh I, Rajesh B, et al. (2007). Transient asymptomatic bradycardia in patients with infusional 5-fluroruracil. J Cancer Res Ther 3:169–71
   PubMedGoogle Scholar
• Valko M, Leibfritz D, Moncol J, et al. (2007). Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39:44–84
   PubMed Web of Science ®Google Scholar
• Walko CM, Lindley C. (2005). Capecitabine: a review. Clin Ther 27:23–44
   PubMed Web of Science ®Google Scholar
• Wasif Saif M, Choma A, Salamone SJ, Chu E. (2009). Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 101:1543–52
   Google Scholar
• Westfall MV, Borton AR. (2003). Role of troponin I phosphorylation in protein kinase C mediated enhanced contractile performance of rat myocytes. J Biol Chem 278:33694–700
   PubMed Web of Science ®Google Scholar
• Westfall MV, Rust EM, Albayya F, Metzger JM. (1997). Adenovirus-mediated myofilament gene transfer into adult cardiac myocytes. Methods Cell Biol 52:307–22
   PubMed Web of Science ®Google Scholar
• Zuppinger C, Timolati F, Suter TM. (2007). Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol 7:61–6
   Google Scholar